05/15/2026
World’s First Dynamic Self-Personalized Drug Achieves Breakthrough Against 90% Fatal MDR Cancer.
From Static Drugs to Dynamic Self-Personalized Medicine – The Paradigm Shift Has Arrived!
At BioNJ on May 12, 2026, Dr. Boris Farber presented TRIZ Biopharma’s groundbreaking MoLRx™ platform — the world’s first dynamic self-personalized drug for Multi-Drug Resistance
(MDR) in lung cancer.
We are not just fighting MDR — we are pioneering the future of medicine.
MoLRx™ transforms the 90% fatal failure of multi-drug resistance into durable life by shifting from static, fixed-molecule drugs to dynamic, self-adaptive therapies that respond in real time
to a patient’s biology and tumor evolution.
This first-in-class platform delivers impressive preclinical results: 100% survival in aggressive MDR models, significant tumor reduction, and extended survival in terminal patients — with
zero approved competitors in this massive untapped market.
This marks the birth of Dynamic Medicine — the future of oncology and beyond.
Dreams are tomorrow’s reality, drafted today.